BioSpace News Archive

Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial.

Immunocore Holdings plc presented three posters about KIMMTRAK® for the treatment of patients with unresectable or metastatic uveal melanoma at the 2024 ASCO Annual Meeting.

Y-mAbs Therapeutics, Inc. announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with relapsed or refractory high-risk neuroblastoma with residual disease limited to bone and/or bone marrow.

Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse.

Bristol Myers Squibb announced results from the Phase 3 KRYSTAL-12 study evaluating KRAZATI® compared to standard of care chemotherapy in patients with locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer who had previously received platinum-based chemotherapy, concurrently or sequentially with anti-PD-1 therapy.

Nuvation Bio Inc. announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its investigational next-generation ROS1 tyrosine kinase inhibitor, were published in the Journal of Clinical Oncology and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place in Chicago, Illinois.

Black Diamond Therapeutics, Inc. presented additional data from the Phase 1 dose escalation trial of BDTX-1535 in patients with recurrent glioblastoma, and initial data from a phase 0/1 “trigger” investigator-sponsored trial at the American Society of Clinical Oncology Annual Meeting.

The American Cancer Society and the American Society of Clinical Oncology announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online.

Genmab A/S and BioNTech SE announced initial data from the ongoing Phase 2 trial evaluating acasunlimab, an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PD-L-positive metastatic non-small cell lung cancer who had disease progression following one or more prior lines of anti-PD1-containing treatment.

Study shows that FPM data can be reliably and quickly generated even through minimally invasive small-needle biopsies, which may expand the accessibility of FPM to provide personalized treatment validation and recommendations. NIMHD-funded study explores the relationship between biomarkers and racial/ethnic differences in response to cancer therapies to address existing health disparities. New research builds on a body of clinical evidence published in the April issue o